Build status - In Progress

A Phase 1 Open-Label Safety Pharmacokinetic and Preliminary Efficacy Study of STRO-002 an Anti-Folate Receptor alpha (FolR) Antibody Drug Conjugate (ADC) in Combination with Bevacizumab in Patients with Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers)

Recruiting
99 years or below
All
Phase 1
5 participants needed
1 Location

Brief description of study

To evaluate the safety and tolerability of STRO-002/bevacizumab as a combination therapy. To further evaluate the toxicity and tolerability of STRO-002/bevacizumab in patients with Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) To characterize the PK of STRO-002 when administered with bevacizumab To assess the immunogenic potential of STRO-002 when administered with bevacizumab.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All
Updated on 10 May 2023. Study ID: 850700

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center